Neutral impactStocks
Pine Labs Rated 'Buy' By Motilal Oswal On Coverage Initiation — Check Target Price
NDTV Profit 1d ago·21 Sept 2026, 5:29 am
The brokerage estimates Pine Labs to deliver a healthy CAGR of 24%/46%/129% in revenue/ adjusted EBITDA/PAT over FY26-28E and adjusted EBITDA margin would improve to 28.7% from 9% in FY24.
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Pine Labs (PINELABS).
- Category: Stocks.
Why it matters
A routine update for Pine Labs. Use the price and stock snapshot to gauge how the market is responding.
